Please select the option that best describes you:
Would you extrapolate IMPower010 data to offer adjuvant atezolizumab to a patient with N2 PDL1-high (>50%) NSCLC who had been treated with induction chemotherapy followed by definitive R0 resection after partial response?
Can atezo be used even if patient has completed chemotherapy preoperatively?
Answer from: Medical Oncologist at Community Practice
As outlined by Dr. @Debora S. Bruno, IMpower010 did not enroll patients who had received neoadjuvant chemotherapy and I fully agree that neoadjuvant chemotherapy + immunotherapy trial would be appealing in patients with N2 disease. Especially, since treatment of these patients is controversial and c...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The IMpower010 study did not enroll patients with N2 disease undergoing neoadjuvant chemotherapy followed by an R0 resection. I agree the biologic concept of using adjuvant atezolizumab in patients with completely resected disease who were treated with neoadjuvant systemic chemotherapy is a similar ...